88
Participants
Start Date
September 30, 2025
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2028
Ivonescimab
Ivonescimab 20 mg/kg by intravenous (IV) infusion once every 2 weeks until disease progression.
FOLFOX regimen
Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour continuous IV infusion, every two weeks for 8 cycles followed by 5FU as maintenance therapy until disease progression.
Irinotecan
180 mg/ m2 IV over 90 min infusion every two weeks for a minimum of 4 cycles
Paclitaxel
80 mg/m2 IV at D1, D8 and D15, every four weeks (D1=D28)
Institut Paoli Calmettes, Marseille
Institut de Cancerologie de l'Ouest - Site René Gauducheau, Saint-Herblain
Collaborators (1)
Summit Therapeutics
INDUSTRY
UNICANCER
OTHER